Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in patients with coronary heart disease and arrhythmia

Gongzhu Han¹, Hong Qiu², Yichun Mao³

¹Department of Cardiology, Jiaozhou Central Hospital of Qingdao, Qingdao 266300, China; ²Department of Pharmacy, Qingdao Municipal Hospital, 266000, Qingdao, Shandong, China; ³Department of Geriatrics, Second Affiliated Hospital of Mudanjiang Medical College, Mudanjiang City 157000, Heilongjiang Province, China.

For correspondence:- Yichun Mao Email: mengxian375494840@163.com

Accepted: 28 August 2023 Published: 30 September 2023

Citation: Han G, Qiu H, Mao Y. Effect of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in patients with coronary heart disease and arrhythmia. Trop J Pharm Res 2023; 22(9):1967-1973 doi: 10.4314/tjpr.v22i9.27

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effects of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in coronary heart disease (CHD) patients with arrhythmia.

Methods: In this retrospective research, a total of 110 CHD and arrhythmia patients on admission at Jiaozhou Central Hospital of Qingdao from June 2020 to June 2022 were randomly but equally divided into control group (CG) treated with propafenone hydrochloride tablets, and study group (SG) treated with a combination of amiodarone hydrochloride tablets and potassium magnesium aspartate. Clinical efficacy of the treatment types as well as the number of premature ventricular contractions (PVC), QTc interval and heart rate (HR) of the patients were monitored to determine left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and cardiac index (CI). Fibrinogen levels, plasma viscosity and hematocrit of the patients were also assessed.

Results: The total effectiveness/efficacy of treatment in SG was 92.73 %, which was significantly higher than the corresponding CG value of 76.36 % (p < 0.05). Relative to CG, PVC and HR in SG were significantly lower, while QTc interval was significantly higher. The levels of LVESD and LVEDD were significantly lower in SG than in CG, while CI level was significantly higher. However, fibrinogen, plasma viscosity and hematocrit values were significantly lower in SG than in CG (p < 0.05).

Conclusion: When administered along with potassium magnesium aspartate in the treatment of CHD and arrhythmia, amiodarone hydrochloride tablets enhances clinical efficacy and improves electrocardiograph index, hemodynamics and cardiac function. Nonetheless, there is need for expanded clinical trials before the use of this treatment strategy in clinical practice.

Keywords: Amiodarone hydrochloride, Potassium magnesium aspartate, Propafenone hydrochloride, Coronary heart disease, Arrhythmia, Hemodynamics, Cardiac function